U.s. commercialization agreement with quallent to drive patient savings with first high-concentration citrate-free interchangeable biosimilar to humira® (adalimumab)

Reykjavik, iceland and parsippany, n.j. and tel aviv, israel, april 30, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), disclosed today that under the recently announced u.s. strategic partnership agreement, alvotech will manufacture its high-concentration interchangeable biosimilar to humira® (adalimumab) for quallent pharmaceuticals, in alignment with its u.s. commercialization agreement with teva. the interchangeable biosimilar will be distributed under quallent's private label.
ALVO Ratings Summary
ALVO Quant Ranking